A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
NCT07754461 · Recruiting
Last updated 2026-08-27This clinical trial is testing whether the medication survodutide helps people with type 2 diabetes better control their blood sugar levels.
What this study is testing ClinicalTrials.gov NCT07754461 ↗
Description as written by the study sponsor.
This study aims to find out whether a study medicine called survodutide helps people control their blood sugar. Adults who live with type 2 diabetes and with a body mass index (BMI) of 23 kg/m2 or higher can join. The study has 3 parts. In each part the study compares survodutide with placebo. Survodutide is being developed to treat several health problems including type 2 diabetes. Placebo looks like survodutide but does not contain any medicine. Depending on a person's diabetes treatment, a person will be assigned either to * Part A: healthy eating and physical activity * Part B: diabetes tablets (no injection of insulin) * Part C: injection of insulin (with or without diabetes tablets) Participants are randomly put into 1 of 3 groups, which means the group is chosen by chance. Two groups of participants get survodutide at different dose levels, and the third group gets placebo as injection under the skin once a week. You have a 2 in 3 chance of getting survodutide. During the study, participants continue their regular diabetes treatment. Participants are in the study for about 1 year and 2 months. During this time, they attend up to 12 visits at the site and receive at least 9 phone calls. Study doctors regularly test participants' blood sugar by checking their HbA1c values and other laboratory test results. The study doctor also regularly checks participants' health and takes note of any changes. For each study part, the results will be compared between the survodutide and the placebo group to see whether the treatment works.
Treatments tested
- Placebo Drug
Placebo
- Survodutide also known as BI 456906 Drug
Survodutide
| Main thing measured | Absolute change in glycosylated haemoglobin A1c (HbA1c) (%) from baseline to Week 41 |
|---|---|
| Sponsor | Boehringer Ingelheim |
| Conditions studied | Type 2 Diabetes |
| GLP-1 drugs | survodutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07754461 ↗